← Leaderboards
Jeffrey Wallace Tyner
Oregon Health & Science University
$13,872,769
Attributed
$23,151,751
Total exposure
15
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,283,944 · 16
By mechanism
U54$15,536,387 · 7
U01$9,859,636 · 2
R01$5,057,094 · 3
T32$2,622,335 · 1
R00$723,254 · 1
K99$255,798 · 1
Top collaborators
- Brian J Druker18 shared
- Bill H Chang5 shared
- Stephen E Kurtz5 shared
- Amanda K Mccullough5 shared
- Shannon K Mcweeney4 shared
- Paul D Piehowski4 shared
- Adam Arne Margolin3 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Julia E Maxson$5,322,132
- Stephen E Kurtz$864,836
- Haijiao Zhang$1,696,427
- Paul D Piehowski$1,534,630
- Zachary David Urdang$188,874
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCellsDrug CombinationsResistanceResponsePathway InteractionsClinical TrialsSignal TransductionLeukemiaDrug SensitivityAcute Myelocytic LeukemiaEvaluationHematologic NeoplasmsSpecimenBiologyCell LineSamplingGenesProgramsValidationDrug ResistancePharmaceutical PreparationsComplexGenetic
Grant awards (64)
Architecture and Trajectory of Acquired Resistance to Therapy in AML$1,308,996
U54 · FY2025 · CA · contact PI
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia$1,168,038
U01 · FY2025 · CA · contact PI
Program in Biomedical Sciences$534,450
T32 · FY2025 · GM · contact PI
Mechanisms of venetoclax combination activity in acute myeloid leukemia$352,275
R01 · FY2025 · CA · contact PI
Trajectory and Architecture of Tumor Intrinsic Drug Resistance in AML$304,093
U54 · FY2025 · CA · contact PI
Core A: Administrative Core$266,487
U54 · FY2025 · CA · contact PI
Translational Oncology Research Program$57,360
P30 · FY2025 · CA · contact PI
Architecture and Trajectory of Acquired Resistance to Therapy in AML$1,243,548
U54 · FY2024 · CA · contact PI
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia$1,109,637
U01 · FY2024 · CA · contact PI
Program in Biomedical Sciences$549,359
T32 · FY2024 · GM · contact PI
Targeting PTPN11 dependent Hematologic Malignancies$334,662
R01 · FY2024 · CA
Mechanisms of venetoclax combination activity in acute myeloid leukemia$334,662
R01 · FY2024 · CA · contact PI
Trajectory and Architecture of Tumor Intrinsic Drug Resistance in AML$291,003
U54 · FY2024 · CA · contact PI
Core A: Administrative Core$253,398
U54 · FY2024 · CA · contact PI
Translational Oncology Research Program$57,360
P30 · FY2024 · CA · contact PI
Architecture and Trajectory of Acquired Resistance to Therapy in AML$1,308,998
U54 · FY2023 · CA · contact PI
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia$1,144,679
U01 · FY2023 · CA · contact PI
Program in Biomedical Sciences$530,535
T32 · FY2023 · GM · contact PI
Mechanisms of venetoclax combination activity in acute myeloid leukemia$345,230
R01 · FY2023 · CA · contact PI
Targeting PTPN11 dependent Hematologic Malignancies$345,230
R01 · FY2023 · CA
Trajectory and Architecture of Tumor Intrinsic Drug Resistance in AML$304,093
U54 · FY2023 · CA · contact PI
Core A: Administrative Core$266,490
U54 · FY2023 · CA · contact PI
Translational Oncology Research Program$57,360
P30 · FY2023 · CA · contact PI
Architecture and Trajectory of Acquired Resistance to Therapy in AML$1,308,998
U54 · FY2022 · CA · contact PI
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia$1,181,536
U01 · FY2022 · CA · contact PI
Program in Biomedical Sciences$520,362
T32 · FY2022 · GM · contact PI
Trajectory and Architecture of Tumor Intrinsic Drug Resistance in AML$369,544
U54 · FY2022 · CA · contact PI
Mechanisms of venetoclax combination activity in acute myeloid leukemia$345,230
R01 · FY2022 · CA · contact PI
Targeting PTPN11 dependent Hematologic Malignancies$345,230
R01 · FY2022 · CA
Core A: Administrative Core$70,138
U54 · FY2022 · CA · contact PI
Translational Oncology Research Program$57,360
P30 · FY2022 · CA · contact PI
Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML$1,154,998
U54 · FY2021 · CA · contact PI
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies$1,004,844
U01 · FY2021 · CA
Program in Biomedical Sciences$487,629
T32 · FY2021 · GM · contact PI
Drug Combinations to Enhance Sensitivity and Circumvent Resistance$379,316
U54 · FY2021 · CA · contact PI
Targeting PTPN11 dependent Hematologic Malignancies$352,275
R01 · FY2021 · CA
Mechanisms of venetoclax combination activity in acute myeloid leukemia$352,275
R01 · FY2021 · CA · contact PI
Dissecting Single-cell Response or resistance to novel combination therapy in AML using mass cytometry$93,333
U54 · FY2021 · CA · contact PI
Administrative Core$93,333
U54 · FY2021 · CA · contact PI
Administrative Core$63,249
U54 · FY2021 · CA · contact PI
Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML$1,154,998
U54 · FY2020 · CA · contact PI
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies$1,004,844
U01 · FY2020 · CA
Drug Combinations to Enhance Sensitivity and Circumvent Resistance$379,315
U54 · FY2020 · CA · contact PI
Targeting PTPN11 dependent Hematologic Malignancies$352,275
R01 · FY2020 · CA
Administrative Core$63,249
U54 · FY2020 · CA · contact PI
Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML$1,248,330
U54 · FY2019 · CA · contact PI
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies$1,236,369
U01 · FY2019 · CA
Drug Combinations to Enhance Sensitivity and Circumvent Resistance$382,392
U54 · FY2019 · CA · contact PI
Administrative Core$63,764
U54 · FY2019 · CA · contact PI
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies$1,004,844
U01 · FY2018 · CA
Pathogenetic Mechanism and Clinical Targeting of CSF3R-Driven Cancer$319,550
R01 · FY2018 · CA · contact PI
Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML$2,309,994
U54 · FY2017 · CA · contact PI
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies$1,004,845
U01 · FY2017 · CA
Drug Combinations to Enhance Sensitivity and Circumvent Resistance$727,831
U54 · FY2017 · CA · contact PI
Pathogenetic Mechanism and Clinical Targeting of CSF3R-Driven Cancer$319,550
R01 · FY2017 · CA · contact PI
Administrative Core$126,499
U54 · FY2017 · CA · contact PI
Pathogenetic Mechanism and Clinical Targeting of CSF3R-Driven Cancer$319,550
R01 · FY2016 · CA · contact PI
Pathogenetic Mechanism and Clinical Targeting of CSF3R-Driven Cancer$319,550
R01 · FY2015 · CA · contact PI
Pathogenetic Mechanism and Clinical Targeting of CSF3R-Driven Cancer$319,550
R01 · FY2014 · CA · contact PI
ROR1 as a Therapeutic Target in Acute Lymphoblastic Leukemia$241,084
R00 · FY2014 · CA · contact PI
ROR1 as a Therapeutic Target in Acute Lymphoblastic Leukemia$233,629
R00 · FY2013 · CA · contact PI
ROR1 as a Therapeutic Target in Acute Lymphoblastic Leukemia$248,541
R00 · FY2012 · CA · contact PI
ROR1 as a Therapeutic Target in Acute Lymphoblastic Leukemia$127,899
K99 · FY2011 · CA · contact PI
ROR1 as a Therapeutic Target in Acute Lymphoblastic Leukemia$127,899
K99 · FY2010 · CA · contact PI